語言:

Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?

Cannon, Michael J. ; Griffiths, Paul D. ; Aston, Van ; Rawlinson, William D.

Reviews in medical virology, 2014-09, Vol.24 (5), p.291-307 [同儕審閱期刊]

可取得全文

引用被引用

傳送到

題名:
Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?
著者: Cannon, Michael J. ; Griffiths, Paul D. ; Aston, Van ; Rawlinson, William D.
主題: Cytomegalovirus ; Cytomegalovirus Infections - complications ; Cytomegalovirus Infections - congenital ; Cytomegalovirus Infections - diagnosis ; Cytomegalovirus Infections - virology ; Humans ; Infant, Newborn ; Neonatal Screening
所屬期刊: Reviews in medical virology, 2014-09, Vol.24 (5), p.291-307
描述: SUMMARY Congenital CMV infection is a leading cause of childhood disability. Many children born with congenital CMV infection are asymptomatic or have nonspecific symptoms and therefore are typically not diagnosed. A strategy of newborn CMV screening could allow for early detection and intervention to improve clinical outcomes. Interventions might include antiviral drugs or nonpharmaceutical therapies such as speech‐language therapy or cochlear implants. Using published data from developed countries, we analyzed existing evidence of potential benefit that could result from newborn CMV screening. We first estimated the numbers of children with the most important CMV‐related disabilities (i.e. hearing loss, cognitive deficit, and vision impairment), including the age at which the disabilities occur. Then, for each of the disabilities, we examined the existing evidence for the effectiveness of various interventions. We concluded that there is good evidence of potential benefit from nonpharmaceutical interventions for children with delayed hearing loss that occurs by 9 months of age. Similarly, we concluded that there is fair evidence of potential benefit from antiviral therapy for children with hearing loss at birth and from nonpharmaceutical interventions for children with delayed hearing loss occurring between 9 and 24 months of age and for children with CMV‐related cognitive deficits. We found poor evidence of potential benefit for children with delayed hearing loss occurring after 24 months of age and for children with vision impairment. Overall, we estimated that in the United States, several thousand children with congenital CMV could benefit each year from newborn CMV screening, early detection, and interventions. Copyright © 2014 John Wiley & Sons, Ltd.
出版者: England: Blackwell Publishing Ltd
語言: 英文
識別號: ISSN: 1052-9276
EISSN: 1099-1654
DOI: 10.1002/rmv.1790
PMID: 24760655
資源來源: Wiley Online Library
Wiley Online Library AutoHoldings Journals

連結

View this record in MEDLINE/PubMed

返回到檢索清單

前一個記錄檢索清單 5 下ㄧ個記錄下ㄧ頁

Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?

Cannon, Michael J. ; Griffiths, Paul D. ; Aston, Van ; Rawlinson, William D.

正在檢索遠程資料庫，請稍等